IPO registrations (S-1, F-1) · Underwriters
Kempen &
- Deals
- 9 priced offerings as an underwriter, 4 as lead manager or representative; 9 initial public offerings
- Proceeds of those deals
- $1,474,058,333 ($394,250,000 as lead)
- Years
- 2019–2021
- Named in
- 16 prospectuses and registration statements in all, including offerings not yet priced or withdrawn
- SEC registration
- Broker-dealer registered as KEMPEN & CO U.S.A., INC. · filings on EDGAR ↗
- Named as
- Kempen &; Kempen & Co; Kempen & Co U.S.A., Inc
Deals by year
Deals 9
| Priced | Company | Role | Price | Range | Shares | Proceeds | Listing | Kind | Syndicate | Prospectus |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-13 | Forbion European Acquisition Corp. E9 | Lead | $10.00 | 11,000,000 | $110,000,000 | Nasdaq FRBN | IPO | 2 | 424B4 ↗ | |
| 2021-11-08 | IO Biotech, Inc. G7 | Syndicate | $14.00 | 7,150,000 | $100,100,000 | Nasdaq IOBT | IPO | 4 | 424B4 ↗ | |
| 2021-06-16 | MOLECULAR PARTNERS AG V8 | Lead | $21.25 | 3,000,000 | $63,750,000 | Nasdaq MOLN | IPO | 5 | 424B4 ↗ | |
| 2021-03-31 | Achilles Therapeutics plc X0 | Syndicate | $18.00 | 9,750,000 | $175,500,000 | Nasdaq ACHL | IPO | 6 | 424B4 ↗ | |
| 2021-03-26 | LAVA Therapeutics NV | Lead | $15.00 | 6,700,000 | $100,500,000 | Nasdaq LVTX | IPO | 4 | 424B4 ↗ | |
| 2021-03-17 | European Biotech Acquisition Corp. V8 | Lead | $10.00 | 12,000,000 | $120,000,000 | Nasdaq EBAC | IPO | 2 | 424B4 ↗ | |
| 2020-10-30 | Damora Therapeutics, Inc. MA | Syndicate | $15.00 | 5,666,667 | $85,000,005 | Nasdaq GLTO | IPO | 4 | 424B4 ↗ | |
| 2020-08-14 | CureVac N.V. | Syndicate | $16.00 | 13,333,333 | $213,333,328 | Nasdaq CVAC | IPO | 4 | 424B4 ↗ | |
| 2019-07-19 | GENMAB A/S G7 | Syndicate | $17.75 | 28,500,000 | $505,875,000 | Nasdaq GMAB | IPO | 8 | 424B4 ↗ |
“Offering” is a priced registered offering that the cover page does not describe as an initial public offering: a follow-on, a resale, or a small company’s best-efforts deal.
Works alongside
| Firm | Deals together | Of which that firm led |
|---|---|---|
| BofA Securities | 4 | 4 |
| Jefferies | 4 | 4 |
| Credit Suisse | 3 | 3 |
| J.P. Morgan | 3 | 3 |
| Leerink Partners | 3 | 3 |
| Cowen | 2 | 2 |
| Morgan Stanley | 2 | 2 |
| RBC Capital Markets | 2 | 1 |
| Chardan | 1 | 0 |
| Danske Markets | 1 | 0 |
| Guggenheim Securities | 1 | 0 |
| H.C. Wainwright | 1 | 0 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Offering terms are read from the cover pages of the registrant's final prospectus (424B4, 424B1) and its latest registration statement before pricing: the price range, the final price, shares offered, gross proceeds (the cover's total, else price times shares), exchange and ticker, and the underwriters named on the cover and in the underwriting table (loader/s1_terms.py). Underwriter names are normalised, so Goldman, Sachs & Co. of 1999 and Goldman Sachs & Co. LLC of 2024 are one firm.